Merck & Co., Inc. $MRK Position Increased by Avaii Wealth Management LLC

Avaii Wealth Management LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 79.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,280 shares of the company’s stock after purchasing an additional 6,775 shares during the period. Merck & Co., Inc. accounts for approximately 0.6% of Avaii Wealth Management LLC’s portfolio, making the stock its 25th biggest position. Avaii Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,608,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Darwin Wealth Management LLC raised its stake in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares in the last quarter. Kilter Group LLC bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $27,000. Bare Financial Services Inc grew its stake in shares of Merck & Co., Inc. by 51.9% in the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after buying an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC increased its holdings in Merck & Co., Inc. by 302.3% in the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after buying an additional 266 shares during the last quarter. Finally, Evolution Wealth Management Inc. acquired a new position in Merck & Co., Inc. in the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the subject of a number of analyst reports. Royal Bank Of Canada assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, February 25th. They issued an “outperform” rating and a $142.00 target price for the company. Barclays initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They set an “overweight” rating and a $140.00 price target on the stock. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their price target for the company from $82.00 to $130.00 in a report on Thursday, December 18th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a research note on Thursday, January 8th. Finally, Wells Fargo & Company upped their price objective on shares of Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $127.13.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck agreed to acquire Terns Pharmaceuticals for about $6.7 billion to add TERN‑701, an investigational CML drug that could meaningfully strengthen Merck’s hematology/oncology lineup ahead of Keytruda’s patent cliff. Merck to Boost Oncology Pipeline With $6.7B Terns Buyout, Stock Up
• Positive Sentiment: Citi raised its price target on MRK to $125 (from $120), reflecting continued analyst recognition of Merck’s profitability and strategic M&A. Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
• Positive Sentiment: Agilent received FDA approval for the PD‑L1 IHC 22C3 pharmDx as a companion diagnostic for Keytruda in esophageal/GEJ carcinoma—supportive for continued clinical use of Keytruda where indicated. This can help sustain Keytruda demand in approved indications near-term. Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx
• Neutral Sentiment: Heightened investor interest and searches on Merck point to increased attention and volume as the market digests the deal and guidance; this can amplify intraday moves but is not directional on fundamentals. Investors Heavily Search Merck & Co., Inc. (MRK)
• Neutral Sentiment: Merck held an M&A investor call and provided materials/transcript — useful for detail but mainly confirms terms and rationale rather than changing the deal. Merck & Co., Inc. (MRK) M&A Call Transcript
• Negative Sentiment: Analysts and media note potential rival interest in Terns; William Blair and others suggest the $53/shr offer may undervalue Terns’ upside, implying Merck could face a bidding contest or need to increase the price. That raises transaction risk and potential dilution/cost. Merck’s $6.7 billion Terns acquisition may face rival interest: Analyst
• Negative Sentiment: An investor‑rights law firm is investigating whether Terns shareholders are getting fair value, which can delay closing or lead to litigation/negotiation that complicates the deal timeline and integration. Terns Pharmaceuticals Investor Alert

Merck & Co., Inc. Stock Down 0.4%

Shares of Merck & Co., Inc. stock opened at $118.90 on Friday. The stock has a market capitalization of $293.97 billion, a P/E ratio of 16.33, a PEG ratio of 2.31 and a beta of 0.27. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The stock has a 50 day moving average price of $116.43 and a two-hundred day moving average price of $101.56. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. During the same quarter last year, the firm posted $1.72 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be paid a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 46.70%.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 121,573 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares of the company’s stock, valued at approximately $8,211,341.40. This trade represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer owned 80,615 shares in the company, valued at $9,825,356.20. The trade was a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.